Følg
Vinay Prasad, MD MPH
Tittel
Sitert av
Sitert av
År
Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs
A Haslam, V Prasad
JAMA network open 2 (5), e192535-e192535, 2019
12772019
Research and development spending to bring a single cancer drug to market and revenues after approval
V Prasad, S Mailankody
JAMA internal medicine 177 (11), 1569-1575, 2017
5462017
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices
V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ...
Mayo Clinic Proceedings, 2013
4512013
The high price of anticancer drugs: origins, implications, barriers, solutions
V Prasad, K De Jesús, S Mailankody
Nature reviews Clinical oncology 14 (6), 381-390, 2017
4462017
Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals
C Kim, V Prasad
JAMA internal medicine 175 (12), 1992-1994, 2015
4342015
The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses
V Prasad, C Kim, M Burotto, A Vandross
JAMA internal medicine 175 (8), 1389-1398, 2015
4092015
Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices
V Prasad, JPA Ioannidis
Implementation Science 9 (1), 1-5, 2014
3822014
Perspective: the precision-oncology illusion
V Prasad
Nature 537 (7619), S63-S63, 2016
3722016
Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology
J Marquart, EY Chen, V Prasad
JAMA oncology 4 (8), 1093-1098, 2018
3712018
Five years of cancer drug approvals: innovation, efficacy, and costs
S Mailankody, V Prasad
JAMA oncology 1 (4), 539-540, 2015
3422015
Precision oncology: origins, optimism, and potential
V Prasad, T Fojo, M Brada
The Lancet Oncology 17 (2), e81-e86, 2016
2802016
Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers
V Prasad
Nature Reviews Clinical Oncology 15 (1), 11-12, 2018
2702018
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
R Kemp, V Prasad
BMC medicine 15, 1-7, 2017
2632017
Prespecified Falsification End PointsCan They Validate True Observational Associations? Prespecified Falsification End Points
V Prasad, AB Jena
JAMA 309 (3), 241-242, 2013
2632013
Reversals of Established Medical Practices: Evidence to Abandon Ship
V Prasad, A Cifu, JPA Ioannidis
JAMA 307 (1), 37-38, 2012
2542012
Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs
A Haslam, J Gill, V Prasad
JAMA network Open 3 (3), e200423-e200423, 2020
2382020
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
A Haslam, SP Hey, J Gill, V Prasad
European Journal of Cancer 106, 196-211, 2019
1992019
Ending medical reversal: improving outcomes, saving lives
VK Prasad, AS Cifu
Johns Hopkins University Press, 2019
1782019
Why cancer screening has never been shown to “save lives”—and what we can do about it
V Prasad, J Lenzer, DH Newman
Bmj 352, 2016
1772016
Examining the use of real‐world evidence in the regulatory process
BK Beaulieu‐Jones, SG Finlayson, W Yuan, RB Altman, IS Kohane, ...
Clinical Pharmacology & Therapeutics 107 (4), 843-852, 2020
1732020
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20